buprenorphine

(redirected from Zubsolv)
Also found in: Dictionary.

buprenorphine

 [bu″prĕ-nor´fēn]
a synthetic opioid agonist-antagonist derived from thebaine, used in the form of the hydrochloride salt as an analgesic for moderate to severe pain and as an anesthesia adjunct. Administered sublingually or by intramuscular or intravenous injection.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

buprenorphine

(byo͞o′prə-nôr′fēn′)
n.
A semisynthetic opioid drug, C29H41NO4, used usually in its hydrochloride form as an analgesic and, in combination with naloxone, for long-term treatment of addiction to opioids such as heroin.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

buprenorphine

A formulation of semi-synthetic opioid which may be superior to methadone in reducing heroin and cocaine abuse/dependence.

Adverse effects
Sedation, constipation.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

buprenorphine

Addiction medicine An agent that may be superior to methadone in ↓ heroin and cocaine abuse Side effects Sedation, constipation. Cf Methadone.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

buprenorphine

A powerful painkilling drug that binds to the body's opioid receptors. It acts for 6–8 hours. Brand names are Subutex, Temgesic and Transtec.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv. Total net sales for 2018 amounted to SEK 783.1 million and the number of employees was 129.
Pharmaceutical company Orexo AB announced Tuesday that it has granted the exclusive rights to commercialise its Zubsolv lead product for the treatment of opioid dependence in Australia and New Zealand to Mundipharma Pty Limited (Mundipharma Australia).
Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery.
The approval of the expanded indication for ZUBSOLV was supported by combined data from the Induction, STabilization, Adherence and Retention Trial (ISTART) (Study OX219-006) and Study OX219-007 which showed excellent results with over 90 percent of patients treated with ZUBSOLV remaining on treatment at Day 3 and using a formulation with a 30 percent lower dose of buprenorphine.
The company is commercializing its proprietary product, Zubsolv (buprenorphine and naloxone), for maintenance treatment of opioid dependence, in the United States.
* In July 2013, Swedish pharmaceutical company Orexo was reported to be entering a new phase with increasing effort towards commercialisation of the company's lead product, Zubsolv (buprenorphine +naloxone) sublingual tablet.
M2 EQUITYBITES-July 10, 2019-Orexo enters into license and supply agreement for Zubsolv in Australia and New Zealand
Global Banking News-July 10, 2019-Orexo enters into license and supply agreement for Zubsolv in Australia and New Zealand
In addition, the main market is the American market for buprenorphine/naloxone products, where the company sells the product Zubsolv.
NORDIC BUSINESS REPORT-December 14, 2018-Orexo announces regaining of rights to Zubsolv in all countries outside the US from Mundipharma
Orexo AB has made changes to Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) managed care formulary position with CVS Caremark for patients suffering from opioid dependence.